<DOC>
	<DOCNO>NCT02177253</DOCNO>
	<brief_summary>The primary objective study compare long-term ( 12-week ) bronchodilator efficacy safety ipratropium bromide / salbutamol combination administer Respimat® 40 mcg / 200 mcg ( one inhalation q.i.d . ) COMBIVENT Inhalation Aerosol ( two inhalation q.i.d . ) , ipratropium bromide Respimat® ( one inhalation q.i.d . ) Placebo formulation patient Chronic Obstructive Pulmonary Disease ( COPD ) . An additional objective show superiority Combivent Respimat compare ipratropium bromide ( 40 mcg ) Respimat . Steady state pharmacokinetics one dose interval follow four week therapy also characterize .</brief_summary>
	<brief_title>Ipratropium Bromide/Salbutamol Delivered Respimat® Inhaler Compared Ipratropium Bromide Respimat® , COMBIVENT® Inhalation Aerosol Placebo Adults With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>All patient must diagnosis COPD follow spirometric criterion : Visit 1 ( Screening ) Visit 2 : Patients must relatively stable , moderate severe airway obstruction FEV1 ≤65 % predict normal FEV1 ≤70 % FVC Male female patient 40 year age old Patients must smoke history ten packyears . A packyear defined equivalent smoke one pack 20 cigarette per day year Patients must able perform pulmonary function test maintain record study period require protocol Patients must able trained proper use MDI ( meter dose inhaler ) Respimat® inhaler All patient must sign Informed Consent Form prior participation trial Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Patients clinically relevant abnormal baseline hematology , blood chemistry urinalysis . If abnormality defines disease list exclusion criterion , patient exclude All patient SGOT ( serum glutamic oxaloacetic transaminase ) &gt; 80 IU/L , SGPT ( serum glutamic pyruvic transaminase ) &gt; 80 IU/L , bilirubin &gt; 2.0 mg/dL creatinine &gt; 2.0 mg/dL exclude regardless clinical condition Patients total blood eosinophil count ≥600/mm3 Patients recent history ( i.e. , one year less ) myocardial infarction Patients recent history ( i.e. , three year less ) heart failure patient cardiac arrhythmia require drug therapy Patients history cancer , treat basal cell carcinoma , within last 5 year Patients history lifethreatening pulmonary obstruction , history cystic fibrosis clinically evident bronchiectasis Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No . 1 Patients history asthma allergic rhinitis Patients history and/or active alcohol drug abuse Patients know active tuberculosis Patients upper low respiratory tract infection COPD exacerbation 6 week prior Screening Visit ( Visit 1 ) baseline period Patients know symptomatic prostatic hypertrophy bladder neck obstruction Patients know narrowangle glaucoma Patients current significant psychiatric disorder Patients regularly use daytime oxygen therapy one hour per day investigator 's opinion unable abstain use oxygen therapy Patients treat cromolyn sodium nedocromil sodium Patients treat antihistamine exclude allergic condition Patients use oral corticosteroid medication unstable dos ( i.e. , less 6 week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day Patients initiate use inhale steroid change dos less 6 week prior Screening Visit ( Visit 1 ) baseline period Patients treat betablocker medication , MAO ( monoamine oxidase ) inhibitor tricyclic antidepressant . Beta blocker eye medication ( e.g. , Betoptic ) treatment nonnarrow angle glaucoma allow Patients change therapeutic plan within last 6 week prior Screening Visit ( Visit 1 ) baseline period Pregnant nursing woman woman childbearing potential use medically approve mean contraception Patients know hypersensitivity anticholinergic drug component ipratropium bromide/salbutamol Respimat® solution ( include BAC ( Benzalkonium chloride ) EDTA ( Ethylenediaminetetraacetic acid ) ) ipratropium bromide/salbutamol MDI component Previous participation study Patients currently participate another study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>